Triheptanoin use for severe neonatal cardiomyopathy secondary to mitochondrial trifunctional protein deficiency: a
John-Anthony Coppola1, Megan Boothe2, Anna McGuinness2
1Congenital Heart Center, Division of Pediatric Cardiology, Departments of Pediatrics, University of Florida, Gainesville, FL, USA.
Abstract:
Mitochondrial trifunctional protein deficiency is a long-chain fatty acid disorder that may include manifestations of severe cardiomyopathy and arrhythmias. The pathophysiology for the severe presentation is unclear but is an indicator for worse outcomes. Triheptanoin, a synthetic medium chain triglyceride, has been reported to reverse cardiomyopathy in some individuals, but there is limited literature in severe cases. We describe a neonatal onset of severe disease whose clinical course was not improved despite mechanical support and triheptanoin.
More Related Videos
11:26Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
Published on: February 13, 2019
07:35Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
